MedTrace Logo

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05521438 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-03-16

No results posted yet for this study

Summary

This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle

Conditions

Interventions

DRUG

QRX003-2% Lotion

QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)

DRUG

QRX003-4% Lotion QAM

QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)

DRUG

Vehicle

Vehicle Lotion

DRUG

QRX003-4% Lotion BID

QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)

Sponsors & Collaborators

  • Quoin Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Tony Andrasfay · Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-23
Primary Completion
2025-12-30
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05521438 on ClinicalTrials.gov